As Canada’s national representative in the World Obesity Federation (formerly IASO), the Canadian Obesity Network is proud to co-host the 13th International Congress on Obesity in Vancouver, 1-4 May 2016.
The comprehensive scientific program will span 6 topic areas:
Track 1: From genes to cells
- For example: genetics, metagenomics, epigenetics, regulation of mRNA and non–coding RNA, inflammation, lipids, mitochondria and cellular organelles, stem cells, signal transduction, white, brite and brown adipocytes
Track 2: From cells to integrative biology
- For example: neurobiology, appetite and feeding, energy balance, thermogenesis, inflammation and immunity, adipokines, hormones, circadian rhythms, crosstalk, nutrient sensing, signal transduction, tissue plasticity, fetal programming, metabolism, gut microbiome
Track 3: Determinants, assessments and consequences
- For example: assessment and measurement issues, nutrition, physical activity, modifiable risk behaviours, sleep, DoHAD, gut microbiome, Healthy obese, gender differences, biomarkers, body composition, fat distribution, diabetes, cancer, NAFLD, OSA, cardiovascular disease, osteoarthritis, mental health, stigma
Track 4: Clinical management
- For example: diet, exercise, behaviour therapies, psychology, sleep, VLEDs, pharmacotherapy, multidisciplinary therapy, bariatric surgery, new devices, e-technology, biomarkers, cost effectiveness, health services delivery, equity, personalised medicine
Track 5: Populations and population health
- For example: equity, pre natal and early nutrition, epidemiology, inequalities, marketing, workplace, school, role of industry, social determinants, population assessments, regional and ethnic differences, built environment, food environment, economics
Track 6: Actions, interventions and policies
- For example: health promotion, primary prevention, interventions in different settings, health systems and services, e-technology, marketing, economics (pricing, taxation, distribution, subsidy), environmental issues, government actions, stakeholder and industry issues, ethical issues
Early-bird registration is now open – click here
Abstract submission deadline is November 30, 2015 – click here
For more information including sponsorship and exhibiting at ICO 2016 – click here
I look forward to welcoming you to Vancouver next year.
Anyone who has closely followed my writings on this topic will know by now that health for a given individual cannot be measured by simply stepping on a scale (or for that matter using a measuring tape).
There are indeed individuals who appear rather healthy even at BMI levels considered to be well into the obesity range (just how many depends on your definition of “healthy”).
In an article and commentary that appears in the American Journal of Epidemiology, Juan Pablo Rey-López and colleagues from the School for Policy Studies, University of Bristol,UK, argue that the notion of “metabolically healthy obesity” (MHO), if anything is distracting and even counterproductive to public health efforts to prevent obesity.
They argue that,
“the MHO phenotype is not benign and as such has very limited relevance as a public health target.”
Throughout the article, the authors indeed make the oft-heard arguments for a population wide approach based on the notion that even a small left-shift in the weight distribution curve (as popularized by Geoffrey Rose) can have a potentially large influence on the population burden of excess weight.
This is not something anyone would argue with – at least at a population level and when the issue is prevention.
Unfortunately, Rey-López and colleagues then fall into the trap of pooh-poohing the research efforts around better trying to understand exactly why there is such a variation in how excess weight may (or may not) affect an individual’s health.
“More efforts must be allocated to reducing the distal and actual causal agents that lead to weight gain, instead of the current disproportionate scientific interest in the biological processes that explain the heterogeneity of obesity.”
Furthermore, they argue against further investments into obesity treatments:
“Nevertheless, it should be openly recognized that further investments in this predominantly individual approach will not reverse the obesity epidemic, because 1) medical therapies or dramatic lifestyle changes do not modify the distal causes of obesity (i.e., modern processed food and the built environment) and 2) individualized lifestyle modifications are commonly unsuccessful and inaccessible.“
The two facts that are largely ignored in this discussion are 1) that efforts at prevention (no matter how effective) are not helping the millions of people already living with this problem and 2) trying to find better treatments by learning more about the biology of this condition is exactly how we have found treatments for a host of other conditions ranging from diabetes to hypercholesterolemia and that these treatments have indeed allowed millions of people with these conditions to live productive and meaningful lives.
Personally, I find that the line of argument presented by the authors reeks of discrimination against people living with this problem. Thus, I cannot help but think that the authors consider people with obesity a “lost cause” not worthy of the investment into finding or providing better treatments.
Whether or not the discussions about MHO will help advance the field or not is certainly debatable.
Wether pitching prevention against treatment has the potential to actually harm people living with this problem is not.
Nevertheless, for what it is worth, a publication by Ruth Brown and colleagues from York University, Toronto, published in Obesity Research and Clinical Practice, suggests that people today may be more susceptible to obesity than just a few decades ago.
The study looks at self-reported dietary from 36,377 U.S. adults from the National Health and Nutrition Survey (NHANES) between 1971 and 2008 and physical activity frequency data from 14,419 adults between 1988 and 2006 (no activity data was available from earlier years).
Between 1971 and 2008, BMI, total caloric intake and carbohydrate intake increased 10-14%, and fat and protein intake decreased 5-9%.
Between 1988 and 2006, frequency of leisure time physical activity increased 47-120%.
However, for a given amount of caloric intake, macronutrient intake or leisure time physical activity, the predicted BMI was up to 2.3kg/m2 higher in 2006 that in 1988.
So unless there was some major systematic shift in what people were reporting (which seems somewhat unlikely) it is clear that factors other than diet and physical activity may be contributing to the increase in BMI over time – or in other words, it appears that people today, for the same caloric intake and physical activity, are more likely to have a higher BMI than people living a few decades ago.
There are of course several plausible biological explanations for these findings including epigenetics, obesogenic environmental toxins, alterations in gut microbiota to name a few.
If nothing else, these data support the notion that there is more to the obesity epidemic than just eating too much and not moving enough.
For readers, who like showing images that demonstrate just how increasingly prevalent obesity is across the US, here are the 2014 obesity maps released by the US Centre for Disease Control this week.
Not that much new (unless you want to quibble about a couple of percent points here or there) – the situation is bad, with no sign of getting any better (no surprise here).
Here are the basic facts:
- No state had a prevalence of obesity less than 20%.
- 5 states and the District of Columbia had a prevalence of obesity between 20% and <25%.
- 23 states, Guam and Puerto Rico had a prevalence of obesity between 25% and <30%.
- 19 states had a prevalence of obesity between 30% and <35%.
- 3 states (Arkansas, Mississippi and West Virginia) had a prevalence of obesity of 35% or greater.
- The Midwest had the highest prevalence of obesity (30.7%), followed by the South (30.6%), the Northeast (27.3%), and the West (25.7%).
What else can one say?
Yes, there is also considerable waste in healthcare systems and not every dollar spent is necessary or provides any meaningful benefit.
Indeed, even where health benefits are achieved, these may perhaps be had at a lower cost than in our current systems.
Thus, there is no argument against reducing waste and improving cost-effectiveness of treatments (or for that matter, prevention).
However, arguing in favour of cost-effectiveness should not be confused with arguments for cost-savings, as is often put forward in discussions about obesity treatment.
Indeed, authors often bend over backwards to demonstrate the potential cost-savings that may come from treating obesity.
Case in point is a study by Oleg Borisenko and colleagues, who in a paper published in Obesity Surgery, suggest that (based on the Scandinavian Bariatric Surgery Registry), surgical treatment of severe obesity led to savings of €8408 per patient, which translates into lifetime savings savings of €66 million for the cohort, operated in 2012.
Be that as it may, I feel that savings cannot be the sole argument in favour of providing treatments for a disease. Given the tremendous impact that obesity has on the health and lives of people living with obesity, I would argue for treatments even if they increase healthcare costs.
Let us remind ourselves that we do not argue about whether or not treating people with heart attacks, osteoarthritis, kidney failure or cancer saves money for the health care system – it rarely does, and is besides the point. The reason we spend money treating these conditions is because the people presenting with these conditions deserve treatment – period!
Thus, I would argue that the primary reason that health care systems should be spending money on treating obesity is because people with obesity deserve treatment – not because it saves money for the system.
Thus, even if there was a net cost to treating obesity, people with obesity deserve treatment as much as people with diabetes, heart disease or chronic kidney disease.
If this means a greater cost to the health care system, so be it – raise taxes or increase payers contributions – don’t try to save money by simply refusing to pay for obesity treatment (or rationing it by making it difficult for patients to access).
Using cost-savings as the prime argument for treating obesity reeks of discrimination.
This is why I refuse to participate in debates about how treating obesity can save health care systems millions of dollars – while this may well be the case, it is not the argument that I am willing to make to justify providing effective medical or surgical care to people living with this condition.